---
document_datetime: 2023-09-21 17:50:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/refludan-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: refludan-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.2525482
conversion_datetime: 2025-12-29 23:09:07.990767
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

## For procedures finalised after 1 August 2003 please refer to module 8B.

- The MAH submitted to the EMEA on 7 April 1997 an application for a Type I variation No 12 of  Annex  I,  (Type  II  procedure  applicable)  minor  change  of  manufacturing  process  of  the active  substance,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10 March 1995. The procedure started on 18 April 1997 and a positive opinion was adopted by the CPMP on 18 June 1997.
- The MAH submitted to the EMEA on 18 April 1997 an application for a Type I variation No 12 of Annex I, (Type II procedure applicable) minor change of manufacturing process of the active substance. The procedure started on 18 April 1997 and a positive opinion was adopted by the CPMP on 18 June 1997.

· The  MAH  submitted  to  the  EMEA  on  4  June  1997  an  application  for  the  transfer  of  the Marketing Authorisation to Hoechst Marion Roussel Deutschland GmbH Germany, pursuant to Article 3 of Commission Regulation (EC) No. 2141/96 of 7 November 1996. The procedure started  on  4  June  1997  and  a  positive  opinion  was  signed  by  the  Executive  Director  at  the EMEA on 6 June 1997. · The MAH submitted to the EMEA on 27 May 1997 an application for a Type I variation No 11 of Annex I, (Type II procedure applicable) change of manufacturer of the active substance, pursuant  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995.  The procedure started on 30 May 1997 and a positive opinion was adopted by the CPMP on 18 June 1997. · The MAH submitted to the EMEA on 27 May 1997 an application for a Type I variation No 1 of Annex I, change of the Manufacturer responsible for batch release, pursuant to Article 4 of Commission Regulation (EC) No. 542/95 of 10 March 1995. The procedure started on 28 May 1997 and a positive opinion was adopted by the CPMP on 6 June 1997. · The MAH submitted to the EMEA on 4 June 1997 an application for a Type I variation No 1 of  Annex  I,  (Type  II  procedure  applicable) change  of  manufacturer  responsible  for  filling, lyophilisation  and  packaging,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No. 542/95 of 10 March 1995. The procedure started on 9 June 1997 and a positive opinion was adopted by the CPMP on 17 June 1997. · The MAH submitted to the EMEA on 1 July 1997 an application for a Type I variation, minor change in the manufacture of the medicinal product, consisting of: -the use of a newly installed separated filling cabin -a new lyophiliser of equivalent make to the previous one in reconstructed building H69 -the  use  of  \"ultraclean\"  rubber  stoppers  of  the  same  type  supplied  by  the  same manufacturer. The variation  relates  to  Article  4  of  Commission  Regulation  (EC)  No.  542/95  of  10  March 1995.  The procedure started on 25 July 1997 and a positive opinion was adopted by the CPMP on 24 September 1997. Medicinal product no longer authorised

- The MAH submitted to the EMEA on 1 July 1998 an application for a Type II variation for an additional fill size (20 mg, 0.4 ml filled volume) in addition to the already approved fill size, pursuant  to  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995.  The procedure started on 24 July 1998 and a positive opinion was adopted by the CPMP on 17 September 1998.

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                     | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Quality changes                                                                                                                                           | II/0010              | II                       | 26.04.01                            | 11.05.01                                 |
| Change in the name of a manufacturer of the active substance                                                                                              | I/0011               | I                        | 31.08.01                            | 19.10.01                                 |
| Changes in the SPC (4.2, 4.3, 4.4, 4.5 and 4.8), Labelling and PL as requested by the CPMP following the assessment of the 5 th PSUR.                     | I/0012               | II                       | 18.10.2001                          | 06.02.02                                 |
| Change in the name and/or address of the marketing authorisation holder, from Hoechst Marion Roussel Deutschland GmbH to Aventis Pharma Deutschland GmbH. | I/0013               | I                        | 03.10.01                            | 20.11.01                                 |
| Renewal                                                                                                                                                   | R/0014               | R                        | 17.01.02                            | 25.04.02                                 |
| Transfer of Marketing Authorisation Holder                                                                                                                | T/0015               | T                        | 21.12.01                            | 19.02.02                                 |
| Urgent Safety Restriction to warn about the risk of anaphylaxis and precautions for re-exposure                                                           | -                    | USR                      | -                                   | -                                        |
| Update of Summary of Product Characteristics and Package Leaflet                                                                                          | II/0016              | II                       | 25.04.03                            | 14.07.03                                 |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                          | N/0017               | N                        | 03.04.03                            | 12.05.03                                 |

Medicinal product no longer authorised

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.